Longboard Pharmaceuticals Inc. (LBPH) Financial Statements (2024 and earlier)

Company Profile

Business Address 4275 EXECUTIVE SQUARE
LA JOLLA, CA 92037
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:48,500,00067,600,000106,700,000
Cash and cash equivalents14,331,00010,775,00066,346,000
Short-term investments34,167,00056,814,00040,379,000
Other undisclosed cash, cash equivalents, and short-term investments2,00011,000(25,000)
Other undisclosed current assets1,721,0002,238,0001,684,000
Total current assets:50,221,00069,838,000108,384,000
Noncurrent Assets
Operating lease, right-of-use asset472,000736,000521,000
Property, plant and equipment4,0009,00014,000
Long-term investments and receivables 33,00033,000
Long-term investments 33,00033,000
Total noncurrent assets:476,000778,000568,000
TOTAL ASSETS:50,697,00070,616,000108,952,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,369,0001,800,0002,860,000
Employee-related liabilities1,480,000
Accounts payable1,001,0001,310,0001,028,000
Accrued liabilities368,000490,000352,000
Other undisclosed current liabilities8,405,0006,964,0002,584,000
Total current liabilities:9,774,0008,764,0005,444,000
Noncurrent Liabilities
Long-term debt and lease obligation:   185,000
Liabilities, other than long-term debt 382,000 
Operating lease, liability 382,000185,000
Total noncurrent liabilities: 382,000370,000
Total liabilities:9,774,0009,146,0005,814,000
Equity
Equity, attributable to parent40,923,00061,470,000103,323,000
Common stock2,0001,0001,000
Additional paid in capital181,563,000148,303,000145,683,000
Accumulated other comprehensive loss(78,000)(692,000)(164,000)
Accumulated deficit(140,564,000)(86,142,000)(42,197,000)
Total equity:40,923,00061,470,000103,323,000
Other undisclosed liabilities and equity   (185,000)
TOTAL LIABILITIES AND EQUITY:50,697,00070,616,000108,952,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Operating expenses(56,759,000)(44,798,000)(27,839,000)
Operating loss:(56,759,000)(44,798,000)(27,839,000)
Loss from continuing operations:(56,759,000)(44,798,000)(27,839,000)
Loss before gain (loss) on sale of properties:(27,839,000)
Other undisclosed net income2,337,000853,00042,000
Net loss:(54,422,000)(43,945,000)(27,797,000)
Other undisclosed net income attributable to parent   
Net loss available to common stockholders, diluted:(54,422,000)(43,945,000)(27,797,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(54,422,000)(43,945,000)(27,797,000)
Comprehensive loss:(54,422,000)(43,945,000)(27,797,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent614,000(528,000)(164,000)
Comprehensive loss, net of tax, attributable to parent:(53,808,000)(44,473,000)(27,961,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: